Dr. Andrew Zelenetz spoke with Cancer Network about the importance of determining the cell of origin in patients with DLBCL.
Andrew Zelenetz, MD, PhD
Advertisement
Articles by Andrew Zelenetz, MD, PhD
The basis for the increased risks of cytomegalovirus and P. carinii infections with DENSE-R-CHOP-14 was puzzling, said Dr. Zelenetz of Memorial Sloan Kettering Cancer Center.
Advertisement
Latest Updated Articles
Determining the Cell of Origin in DLBCLSeptember 26th 2018
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Clears Investigator-Initiated IND for SRN-101 in Recurrent High-Grade Glioma
2
The Evolution of Artificial Intelligence in Oncology: Impact on Trials, Workflows, and Outcomes
3
FDA Approves Relacorilant Combo in Platinum-Resistant Ovarian Cancers
4
Navigating New Horizons in Neuroendocrine Prostate Cancer
5